Peripheral primitive neuroectodermal tumors (pPNETs) are small embryonic carcinomas that develop in the soft tissue and bone, away from the central nervous system (CNS) and sympathetic nervous system ...
Cabozantinib significantly improved progression free survival in patients with pNET and epNET compared with placebo. The Food and Drug Administration (FDA) has approved Cabometyx ® (cabozantinib) for ...
Selecting the Next Line of Therapy After SSA and PRRT in Progressive Pancreatic Neuroendocrine Tumor
This section focuses on the clinical decision making process following progression on lanreotide and lutetium Lu 177 dotatate ...
Newly updated guidelines on neuroendocrine tumors developed by an expert at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and collaborators provide ...
The US Food and Drug Administration (FDA) has approved cabozantinib (Cabometyx, Exelixis, Inc.) for certain adults and children aged ≥ 12 years with previously treated, well-differentiated pancreatic ...
On Thursday, Montrose Regional Health (MRH) announced that it is now offering DOTATATE PET/CET scans to better evaluate and detect certain cancers, such as neuroendocrine tumors (NETs), and provide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results